bullish
Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction
282 Views14 Sep 2022 19:38
SUMMARY
- Biocon Ltd (BIOS IN) divested 5.4% stake in Syngene International Ltd (SYNG IN) and raised INR12.2B. The proceed will be used to finance Biocon’s acquisition of biologics business of Viatris.
- Biocon is still working on the equity-debt split of Viatris deal, and a final decision on the same will be announced soon.
- The strategic deal with Viatris will transform Biocon Biologics into a leading vertically integrated global biologics company, with one of the broadest and deepest commercialized biosimilars portfolio in the industry.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction14 Sep 2022
x